caBozantinib in Pre-treated pAtients With Metastatic COlorectal Cancer.

Summary

This is a phase II non-randomised and non-comparative study, in pretreated mCRC patients, progressed after at least 2 lines of prior chemotherapy for metastatic disease. Treatment plan: * First Stage: A total of 22 patients will be enrolled in the first stage to detect at least 3 patients free of progression at 16 weeks * Second Stage: If at least 3 patients will be free of progression at 16 weeks, an additional cohort of 11 patients will be enrolled in the second stage

Timeline

Start

2019-09-01

Primary completion

2024-12-31

Completion

2024-12-31

Drugs

Indications